Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying user area

Try for free

Pfizer Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Pfizer Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term borrowings, including current portion of long-term debt
Trade accounts payable
Dividends payable
Income taxes payable
Accrued compensation and related items
Deferred revenues
Other current liabilities
Current liabilities
Long-term debt, excluding current portion
Pension and postretirement benefit obligations
Noncurrent deferred tax liabilities
Other taxes payable
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Common stock, $0.05 par value
Additional paid-in capital
Treasury stock, shares at cost
Retained earnings
Accumulated other comprehensive loss
Total Pfizer Inc. shareholders’ equity
Equity attributable to noncontrolling interests
Total equity
Total liabilities and equity

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Short-term borrowings, including current portion of long-term debt
This metric exhibited a fluctuating trend, initially decreasing from 1.75% in 2020 to 1.23% in 2021, then increasing to a notable peak of 4.57% in 2023 before declining to 3.25% in 2024.
Trade accounts payable
The proportion gradually increased from 2.79% in 2020 to 3.45% in 2022, followed by a decline over the next two years to 2.64% in 2024.
Dividends payable
There was a consistent decline in this liability item from 1.40% in 2020 to a low of 1.05% in 2023, with a slight uptick to 1.14% in 2024.
Income taxes payable
This category showed a steady rising trend, increasing from 0.68% in 2020 to 1.36% in 2024, indicating growing tax obligations relative to total liabilities and equity.
Accrued compensation and related items
Values declined gradually from 1.98% in 2020 to 1.23% in 2023, but rebounded to 1.80% in 2024.
Deferred revenues
This liability increased significantly from 0.72% in 2020 to 1.69% in 2021, then steadily declined to 0.71% in 2024, suggesting reduction in deferred income over time.
Other current liabilities
There was a pronounced spike in 2021 at 13.74%, up from 7.47% in 2020, followed by a gradual decrease to 9.24% in 2024, yet remaining well above 2020 levels.
Current liabilities
The share of current liabilities relative to total liabilities and equity increased sharply from 16.81% in 2020 to 23.51% in 2021, then declined moderately to 20.15% by 2024.
Long-term debt, excluding current portion
This component decreased from 24.08% in 2020 to 16.68% in 2022, followed by a substantial increase to 27.17% in 2023, slightly easing to 26.90% in 2024.
Pension and postretirement benefit obligations
A consistent downward trajectory is observed, falling from 3.51% in 2020 to 0.96% in 2023, with a marginal increase to 0.99% in 2024.
Noncurrent deferred tax liabilities
This figure showed volatility, sharply declining from 2.63% in 2020 to 0.19% in 2021, with minor fluctuations thereafter and a rise to 0.99% in 2024.
Other taxes payable
A steady decrease occurred from 7.50% in 2020 to 2.86% in 2024, indicating reduced tax-related liabilities over the period.
Other noncurrent liabilities
This liability increased from 4.32% in 2020 to 7.30% in 2023, then slightly declined to 6.63% in 2024.
Noncurrent liabilities
The overall share decreased from 42.04% in 2020 to 29.99% in 2022, followed by a sharp increase to 39.48% in 2023 and a slight decrease to 38.38% in 2024.
Total liabilities
The total liabilities ratio fluctuated, decreasing from 58.84% in 2020 to 51.36% in 2022, then rising again to 60.58% in 2023 and settling at 58.53% in 2024.
Common stock, $0.05 par value
This component showed a slight but steady decline from 0.30% in 2020 to 0.21% in 2023, with a minor increase to 0.22% in 2024.
Additional paid-in capital
A downward trend is evident, dropping from 57.50% in 2020 to 40.90% in 2023, followed by a partial recovery to 43.86% in 2024.
Treasury stock, shares at cost
The negative percentage decreased in magnitude from -71.96% in 2020 to -50.55% in 2023, then increased again negatively to -53.78% in 2024, reflecting repurchase activity fluctuations.
Retained earnings
This item showed variability, declining from 62.74% in 2020 to 56.97% in 2021, rising to 63.72% in 2022, then falling sharply to 52.25% in 2023 and partially recovering to 54.70% in 2024.
Accumulated other comprehensive loss
The loss narrowed considerably from -7.58% in 2020 to -3.25% in 2021, then fluctuated moderately around -3.5% through 2024.
Total shareholders’ equity
Total equity fluctuated, increasing from 41.00% in 2020 to 48.51% in 2022, before declining to 39.30% in 2023 and rising again to 41.33% in 2024.
Equity attributable to noncontrolling interests
This minor component remained fairly stable, showing a slight decline from 0.15% in 2020 to 0.12% in 2023, with a slight uptick to 0.14% in 2024.
Total equity
Total equity displayed a parallel trend to total Pfizer shareholders' equity, rising from 41.16% in 2020 to a peak of 48.64% in 2022, declining to 39.42% in 2023, and recovering to 41.47% in 2024.
Total liabilities and equity
The sum of liabilities and equity consistently equals 100% across all years, confirming the data's completeness and balance.